Alphyn is developing a pipeline of unique multi-target topical therapeutics for dermatology. Our Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action, to treat individual diseases in multiple ways. Importantly, our Platform drugs have strong safety, side effect, patient tolerability profiles.

Alphyn’s first drug, ZH, completed Phase 2a clinical trials in atopic dermatitis (AD) ($41B market). Results showed superiority to competitors, indicating ZH potential as “drug of choice”.  Phase 2b clinical trial underway with blinded results better than Phase 2a. ZH directly treats AD’s four interconnected problems: inflammation, bacteria, itch, and dry skin. To be effective, an AD drug must directly treat all. Competitive AD drugs primarily direct-target only inflammation.

Alphyn’s second drug (molluscum) completed proof-of-concept human trials; results superior to current therapies paving the way to breakthrough treatment.